TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 2884454

Group type: EXPERIMENTAL
Intervention: 5 mg 33B3.1 daily by intravenous infusion for 14 days (group A)
Number of subjects: 27

Group type: EXPERIMENTAL
Intervention: 10 mg 33B3.1 daily by intravenous infusion for 14 days (group B)
Number of subjects: 27

Group type: COMPARATOR
Intervention: Historical control patients (prednisone/azathioprine)
Number of subjects: 27

Group type: COMPARATOR
Intervention: Patients previously treated with ATG
Number of subjects: 27
Study: 31707498

Group type: EXPERIMENTAL
Intervention: Clobetasol lotion
Number of subjects: 42

Group type: EXPERIMENTAL
Intervention: Squill extract
Number of subjects: 42
Study: 29616028

Group type: EXPERIMENTAL
Intervention: Direct-acting antiviral (DAA) drug therapies
Number of subjects: 31

Group type: COMPARATOR
Intervention: Chronic HCV infection
Number of subjects: 31

Group type: COMPARATOR
Intervention: HCV clearance by DAA drug therapy
Number of subjects: 31
Study: 28931439

Group type: EXPERIMENTAL
Intervention: Whole body vibration (WBV) exercise for 12 weeks
Number of subjects: 180

Group type: EXPERIMENTAL
Intervention: Lower extremity resistance training for 12 weeks
Number of subjects: 180

Group type: COMPARATOR
Intervention: Health education for 12 weeks
Number of subjects: 180
Study: 25285994

Group type: EXPERIMENTAL
Intervention: Oral supplement containing Phyllanthus emblica (100 mg), vitamin E (10 mg), and carotenoids (4.7 mg) three times/day for 6 months
Number of subjects: 65

Group type: COMPARATOR
Intervention: Control group (not treated with antioxidants)
Number of subjects: 65
Study: 23222000

Group type: EXPERIMENTAL
Intervention: Higher leptin levels (T3 vs T1)
Number of subjects: 15

Group type: EXPERIMENTAL
Intervention: Higher leptin levels (T3 vs T1) after adjustment for BMI
Number of subjects: 15

Group type: COMPARATOR
Intervention: Adiponectin and HMW adiponectin
Number of subjects: 15
Study: 22081178

Group type: EXPERIMENTAL
Intervention: Famciclovir plus prednisolone
Number of subjects: 68

Group type: COMPARATOR
Intervention: Prednisolone alone
Number of subjects: 68
Study: 18457936

Group type: EXPERIMENTAL
Intervention: Amoxicillin three-times-daily (TD)
Number of subjects: 155

Group type: EXPERIMENTAL
Intervention: Roxithromycin once-daily (OD)
Number of subjects: 155

Group type: COMPARATOR
Intervention: Placebo once-daily (OD)
Number of subjects: 155

Group type: COMPARATOR
Intervention: Placebo three-times-daily (TD)
Number of subjects: 155
Study: 16935049

Group type: EXPERIMENTAL
Intervention: Resistive exercise program (9-month standardized home-based program starting 3 months after surgery)
Number of subjects: 39

Group type: COMPARATOR
Intervention: Conventional physiotherapy (PT)
Number of subjects: 39
Study: 12891825

Group type: EXPERIMENTAL
Intervention: Red palm oil supplementation (2,400 micrograms of beta-carotene)
Number of subjects: 170

Group type: COMPARATOR
Intervention: Groundnut oil (control)
Number of subjects: 170

Group type: EXPERIMENTAL
Intervention: Red palm oil supplementation
Number of subjects: 170
Study: 10849375

Group type: EXPERIMENTAL
Intervention: Azathioprine
Number of subjects: 28

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 28
Study: 9440634

Group type: EXPERIMENTAL
Intervention: Gastrin-17 (15 pmol/kg/hr)
Number of subjects: 9

Group type: COMPARATOR
Intervention: Control (saline infusion)
Number of subjects: 9
Study: 29633652

Group type: EXPERIMENTAL
Intervention: Music Therapy Group (MTG) - 10 individual sessions of music therapy (30-40 minutes each) with a trained music therapist.
Number of subjects: 116

Group type: COMPARATOR
Intervention: Control Group (CG) - standard care without music therapy.
Number of subjects: 116
Study: 27793197

Group type: EXPERIMENTAL
Intervention: Self-administered acupressure intervention
Number of subjects: 200

Group type: COMPARATOR
Intervention: Wait-list control
Number of subjects: 200
Study: 25285887

Group type: EXPERIMENTAL
Intervention: Tat1-86 (25 μg)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: gp120 (100 ng)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Vehicle
Number of subjects: 0
Study: 23213977

Group type: EXPERIMENTAL
Intervention: Acupoint application during the dog days and the three nine-day periods after the winter solstice (group A)
Number of subjects: 152

Group type: COMPARATOR
Intervention: Acupoint application during the dog days only (group B)
Number of subjects: 152
Study: 19694216

Group type: EXPERIMENTAL
Intervention: Simvastatin (40 mg/d) for 3 months
Number of subjects: 30
Study: 16796606

Group type: EXPERIMENTAL
Intervention: Insulin infusion (steady-state concentration of 100 mU L(-1))
Number of subjects: 9

Group type: COMPARATOR
Intervention: Saline infusion (control)
Number of subjects: 9

Group type: EXPERIMENTAL
Intervention: Insulin infusion
Number of subjects: 9
Study: 15200183

Group type: EXPERIMENTAL
Intervention: Ropivacaine
Number of subjects: 40

Group type: COMPARATOR
Intervention: Bupivacaine
Number of subjects: 40
Study: 11389245

Group type: EXPERIMENTAL
Intervention: Manual pump (MP; Avent ISIS)
Number of subjects: 145

Group type: COMPARATOR
Intervention: Electric pump (EP; Egnell)
Number of subjects: 145
Study: 9227168

Group type: EXPERIMENTAL
Intervention: Corticosteroid (triamcinolone acetonide, TA) injection
Number of subjects: 16

Group type: EXPERIMENTAL
Intervention: Yttrium-90 plus corticosteroid (TA+Y) injection
Number of subjects: 16
Study: 8215545

Group type: EXPERIMENTAL
Intervention: Budesonide (400-800 micrograms/day)
Number of subjects: 40

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 40

Group type: EXPERIMENTAL
Intervention: Budesonide
Number of subjects: 40
Study: 3632371

Group type: EXPERIMENTAL
Intervention: CR-5 (controlled release levodopa-carbidopa)
Number of subjects: 15

Group type: COMPARATOR
Intervention: Sinemet (levodopa-carbidopa)
Number of subjects: 15
Study: 28898536

Group type: EXPERIMENTAL
Intervention: Naloxegol 12.5 mg
Number of subjects: 1352

Group type: EXPERIMENTAL
Intervention: Naloxegol 25 mg
Number of subjects: 1352

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 1352
Study: 27396361

Group type: EXPERIMENTAL
Intervention: Cold-Water Immersion (CWI)
Number of subjects: 10

Group type: COMPARATOR
Intervention: Whole-Body Cryotherapy (WBC)
Number of subjects: 10
Study: 26135351

Group type: EXPERIMENTAL
Intervention: 1 mg crystalline vitamin B‐12 daily for 12 months
Number of subjects: 201

Group type: COMPARATOR
Intervention: Matching placebo
Number of subjects: 201
Study: 23096251

Group type: EXPERIMENTAL
Intervention: Ospemifene 30 mg/day
Number of subjects: 180

Group type: EXPERIMENTAL
Intervention: Ospemifene 60 mg/day
Number of subjects: 180

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 180
Study: 20962160

Group type: EXPERIMENTAL
Intervention: Iron-fortified biscuits (20 mg Fe/d, 4 times/week)
Number of subjects: 139

Group type: EXPERIMENTAL
Intervention: Iron-fortified biscuits
Number of subjects: 139

Group type: COMPARATOR
Intervention: Non-fortified biscuits
Number of subjects: 139
Study: 18785059

Group type: EXPERIMENTAL
Intervention: CHO‐E solution (6% carbohydrate, 50 mg Na/500 ml)
Number of subjects: 10

Group type: COMPARATOR
Intervention: Placebo (non‐CHO‐E)
Number of subjects: 10

Group type: COMPARATOR
Intervention: No fluid
Number of subjects: 10
Study: 16598386

Group type: COMPARATOR
Intervention: Topical metronidazole (Noritate 1% Cream, MetroCream 0.75% Cream, MetroLotion 0.75% Lotion, Metrogel 0.75% and 1% Topical Gel)
Number of subjects: 0
Study: 12769218

Group type: EXPERIMENTAL
Intervention: Dermabond closure (TA)
Number of subjects: 46

Group type: COMPARATOR
Intervention: Subcuticular closure (SC)
Number of subjects: 46
Study: 10671842

Group type: EXPERIMENTAL
Intervention: Needleless injector (J-Tip)
Number of subjects: 72

Group type: COMPARATOR
Intervention: Conventional syringe and 25 G needle
Number of subjects: 72
Study: 9323734

Group type: EXPERIMENTAL
Intervention: Acuvue lenses with UV blocker
Number of subjects: 94

Group type: COMPARATOR
Intervention: Conventional Acuvue lenses without UV blocker
Number of subjects: 94
Study: 8222891

Group type: EXPERIMENTAL
Intervention: Andriol
Number of subjects: 62

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 62
Study: 3094139

Group type: EXPERIMENTAL
Intervention: Imipenem/cilastatin 500/500 mg q6h (77 patients, 56 evaluable for efficacy)
Number of subjects: 163

Group type: COMPARATOR
Intervention: Gentamicin 1.5 mg/kg plus clindamycin 600 mg q6h (86 patients, 62 evaluable for efficacy)
Number of subjects: 163
Study: 30508538

Group type: EXPERIMENTAL
Intervention: Sublingual high-dose liquid birch pollen extract (40,000 AUN/mL)
Number of subjects: 406
Study: 28699560

Group type: EXPERIMENTAL
Intervention: Community mobilisation for dengue prevention (specific details not provided)
Number of subjects: 55723
Study: 25668402

Group type: EXPERIMENTAL
Intervention: LHTLH (live high-train low in hypoxia)
Number of subjects: 32

Group type: EXPERIMENTAL
Intervention: LHTL (live high-train low in normoxia)
Number of subjects: 32

Group type: COMPARATOR
Intervention: LLTL (live low-train low)
Number of subjects: 32

Group type: EXPERIMENTAL
Intervention: Both hypoxic groups (LHTLH and LHTL)
Number of subjects: 32

Group type: EXPERIMENTAL
Intervention: LHTLH
Number of subjects: 32

Group type: EXPERIMENTAL
Intervention: LHTL
Number of subjects: 32

Group type: COMPARATOR
Intervention: LLTL
Number of subjects: 32

Group type: EXPERIMENTAL
Intervention: LHTLH and LHTL
Number of subjects: 32
Study: 23480673

Group type: EXPERIMENTAL
Intervention: Home-based progressive resistance training (N=26)
Number of subjects: 50

Group type: COMPARATOR
Intervention: Standard rehabilitation (N=24)
Number of subjects: 50
Study: 22159775

Group type: EXPERIMENTAL
Intervention: Medical Nutrition Therapy (MNT)
Number of subjects: 147

Group type: COMPARATOR
Intervention: Control group (nutrition information at enrollment)
Number of subjects: 147
Study: 18839644

Group type: EXPERIMENTAL
Intervention: Oral thiocolchicoside (TC) for one week
Number of subjects: 60

Group type: COMPARATOR
Intervention: Adrenergic alpha 2 agonist tizanidine (TZ) for one week
Number of subjects: 60

Group type: COMPARATOR
Intervention: Comparison of TC and TZ
Number of subjects: 60
Study: 16863605

Group type: EXPERIMENTAL
Intervention: Primary percutaneous coronary intervention (PCI)
Number of subjects: 102

Group type: COMPARATOR
Intervention: Conservative therapy
Number of subjects: 102
Study: 15159538

Group type: EXPERIMENTAL
Intervention: Lysine fortification
Number of subjects: 0
Study: 11294048

Group type: EXPERIMENTAL
Intervention: Candesartan 16 mg
Number of subjects: 200

Group type: EXPERIMENTAL
Intervention: Lisinopril 20 mg
Number of subjects: 200

Group type: EXPERIMENTAL
Intervention: Candesartan 16 mg and Lisinopril 20 mg (combination treatment)
Number of subjects: 200
Study: 9272261

Group type: EXPERIMENTAL
Intervention: Fluoxetine 3 x 20 mg/day
Number of subjects: 67

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 67
Study: 7688008

Group type: EXPERIMENTAL
Intervention: Trimipramine
Number of subjects: 37

Group type: COMPARATOR
Intervention: Doxepin
Number of subjects: 37
Study: 3563441

Group type: EXPERIMENTAL
Intervention: Patients classified as 'good'
Number of subjects: 60

Group type: COMPARATOR
Intervention: Patients classified as 'bad'
Number of subjects: 60
Study: 30845044

Group type: EXPERIMENTAL
Intervention: Ottawa Surgical Competency Operating Room Evaluation (O-Score) assessments
Number of subjects: 294

Group type: EXPERIMENTAL
Intervention: P-score evaluations
Number of subjects: 294

Group type: EXPERIMENTAL
Intervention: Combined OP-score instrument (modified O-score and P-score)
Number of subjects: 294
Study: 27080737

Group type: EXPERIMENTAL
Intervention: Psyllium (n = 37)
Number of subjects: 103

Group type: COMPARATOR
Intervention: Placebo (maltodextrin, n = 47)
Number of subjects: 103
Study: 25920634

Group type: EXPERIMENTAL
Intervention: Leukocyte-poor (type-4B) PRP injection
Number of subjects: 25

Group type: COMPARATOR
Intervention: Bupivacaine injection
Number of subjects: 25
Study: 24029010

Group type: EXPERIMENTAL
Intervention: Action observation training
Number of subjects: 30

Group type: COMPARATOR
Intervention: Motor imagery training
Number of subjects: 30
Study: 21193183

Group type: EXPERIMENTAL
Intervention: Trauma exposure and PTSD assessment
Number of subjects: 110

Group type: EXPERIMENTAL
Intervention: PTSD presence
Number of subjects: 110
Study: 19684043

Group type: EXPERIMENTAL
Intervention: Corifollitropin alfa (150 microg single injection)
Number of subjects: 1506

Group type: COMPARATOR
Intervention: Recombinant FSH (200 IU daily injections)
Number of subjects: 1506

Group type: EXPERIMENTAL
Intervention: Corifollitropin alfa
Number of subjects: 1506

Group type: EXPERIMENTAL
Intervention: Corifollitropin alfa and rFSH
Number of subjects: 1506
Study: 18405128

Group type: EXPERIMENTAL
Intervention: Impaired glucose tolerance (IGT)
Number of subjects: 1659

Group type: EXPERIMENTAL
Intervention: Early glucose intolerance (EGI)
Number of subjects: 1659

Group type: COMPARATOR
Intervention: Normal glucose tolerance (NGT)
Number of subjects: 1659

Group type: EXPERIMENTAL
Intervention: Insulin resistance (IR)
Number of subjects: 1659

Group type: EXPERIMENTAL
Intervention: Insulinogenic index
Number of subjects: 1659

Group type: EXPERIMENTAL
Intervention: Survival time free from diabetes
Number of subjects: 1659

Group type: EXPERIMENTAL
Intervention: EGI
Number of subjects: 1659
Study: 15033497

Group type: EXPERIMENTAL
Intervention: Exposure and Response Prevention (ER)
Number of subjects: 43

Group type: EXPERIMENTAL
Intervention: Habit Reversal (HR)
Number of subjects: 43
Study: 11878407

Group type: EXPERIMENTAL
Intervention: Ritonavir 400 mg/saquinavir 400 mg twice daily plus one NRTI
Number of subjects: 90

Group type: COMPARATOR
Intervention: Indinavir 800 mg once every 8 hours plus two NRTIs
Number of subjects: 90
Study: 9894650

Group type: EXPERIMENTAL
Intervention: Transvenous lead system with additional subcutaneous lead
Number of subjects: 20

Group type: COMPARATOR
Intervention: Transvenous lead system only
Number of subjects: 20
Study: 8000154

Group type: EXPERIMENTAL
Intervention: Increased trace element intake (4.5 mg Cu, 190 micrograms Se, and 40 mg Zn/day)
Number of subjects: 10

Group type: COMPARATOR
Intervention: Standard trace element intake (control group)
Number of subjects: 10
Study: 3276620

Group type: EXPERIMENTAL
Intervention: Nitrendipine (20 mg/day)
Number of subjects: 34

Group type: COMPARATOR
Intervention: Atenolol (100 mg/day)
Number of subjects: 34
Study: 31608373

Group type: EXPERIMENTAL
Intervention: Program 4 (community-based HIV care program + nutritional education + food supplement)
Number of subjects: 600

Group type: EXPERIMENTAL
Intervention: Programs 3 (community-based HIV care program + food supplement) and 4 (all elements of Programs 1-3)
Number of subjects: 600

Group type: COMPARATOR
Intervention: Program 1 (community-based HIV care program)
Number of subjects: 600
Study: 29055711

Group type: EXPERIMENTAL
Intervention: del Nido (DN) cardioplegia
Number of subjects: 100

Group type: COMPARATOR
Intervention: St Thomas (STH) cardioplegia
Number of subjects: 100
Study: 26009908

Group type: EXPERIMENTAL
Intervention: PRF+ (Platelet-rich fibrin applied)
Number of subjects: 20

Group type: COMPARATOR
Intervention: PRF- (No platelet-rich fibrin applied)
Number of subjects: 20
Study: 23829407

Group type: EXPERIMENTAL
Intervention: Nurse-led education and psychosocial support programme
Number of subjects: 155

Group type: COMPARATOR
Intervention: Usual care (Control)
Number of subjects: 155
Study: 21564071

Group type: EXPERIMENTAL
Intervention: Methotrexate 15 mg weekly for 8 weeks, then 15 mg weekly for ER, 20 mg weekly for 4 weeks for LR, or 25 mg weekly for LN if not achieving PASI 50.
Number of subjects: 103

Group type: EXPERIMENTAL
Intervention: Methotrexate 20 mg weekly for late responders (LR) after initial 15 mg weekly.
Number of subjects: 103

Group type: EXPERIMENTAL
Intervention: Methotrexate 25 mg weekly for late nonresponders (LN) if not achieving PASI 50 at week 12.
Number of subjects: 103
Study: 19097663

Group type: EXPERIMENTAL
Intervention: Meal tolerance test (MTT)
Number of subjects: 200

Group type: EXPERIMENTAL
Intervention: Model-based parameters during MTT
Number of subjects: 200

Group type: COMPARATOR
Intervention: Oral glucose tolerance test (OGTT)
Number of subjects: 200
Study: 16854694

Group type: EXPERIMENTAL
Intervention: Vibroacoustic stimulation
Number of subjects: 60

Group type: EXPERIMENTAL
Intervention: Halogen light stimulation
Number of subjects: 60

Group type: COMPARATOR
Intervention: No stimulation
Number of subjects: 60
Study: 14514222

Group type: EXPERIMENTAL
Intervention: 2.8 mm neck implants
Number of subjects: 12

Group type: COMPARATOR
Intervention: Neck implants
Number of subjects: 12
Study: 11097959

Group type: EXPERIMENTAL
Intervention: Antidepressant treatment for 12 weeks
Number of subjects: 65

Group type: COMPARATOR
Intervention: Control group (20 elderly comparison subjects)
Number of subjects: 65
Study: 9357931

Group type: EXPERIMENTAL
Intervention: Gestational age groups (25-28 weeks and 28-30 weeks)
Number of subjects: 100

Group type: COMPARATOR
Intervention: Sick infants
Number of subjects: 100

Group type: COMPARATOR
Intervention: Healthy infants
Number of subjects: 100

Group type: EXPERIMENTAL
Intervention: rT3 levels
Number of subjects: 100
Study: 8403788

Group type: EXPERIMENTAL
Intervention: Hormone infusion study (glucagon, adrenaline, noradrenaline, cortisol, growth hormone)
Number of subjects: 10

Group type: COMPARATOR
Intervention: Hypoglycaemia study (plasma glucose lowered to 2.8 mmol/l)
Number of subjects: 10
Study: 6325525

Group type: COMPARATOR
Intervention: American Heart Association Hyperlipidemia Diet C (AHA, N = 23)
Number of subjects: 50

Group type: EXPERIMENTAL
Intervention: Higher fiber, low fat diet based on the Pritikin maintenance diet (HFD, N = 27)
Number of subjects: 50
Study: 30877742

Group type: EXPERIMENTAL
Intervention: M-mZnO (20.90 m2/g)
Number of subjects: 480

Group type: EXPERIMENTAL
Intervention: Micronized ZnO groups (S-mZnO, M-mZnO, L-mZnO)
Number of subjects: 480

Group type: COMPARATOR
Intervention: Control group (ZnSO4)
Number of subjects: 480
Study: 29176386

Group type: EXPERIMENTAL
Intervention: Percentages of maximal voluntary isometric contraction (MVIC)
Number of subjects: 20

Group type: EXPERIMENTAL
Intervention: Ratings of perceived exertion (RPE)
Number of subjects: 20
Study: 26414653

Group type: EXPERIMENTAL
Intervention: Etoricoxib (90 mg)
Number of subjects: 100

Group type: COMPARATOR
Intervention: Diclofenac (75 mg)
Number of subjects: 100

Group type: EXPERIMENTAL
Intervention: Etoricoxib (90 mg) and Diclofenac (75 mg)
Number of subjects: 100
Study: 24671918

Group type: EXPERIMENTAL
Intervention: Radial access (TR)
Number of subjects: 103

Group type: COMPARATOR
Intervention: Femoral access (TF)
Number of subjects: 103

Group type: EXPERIMENTAL
Intervention: Both TR and TF
Number of subjects: 103
Study: 20553134

Group type: EXPERIMENTAL
Intervention: 2% lidocaine with 1:100,000 epinephrine
Number of subjects: 60

Group type: EXPERIMENTAL
Intervention: 4% prilocaine with 1:200,000 epinephrine
Number of subjects: 60

Group type: EXPERIMENTAL
Intervention: 4% prilocaine
Number of subjects: 60
Study: 15585547

Group type: EXPERIMENTAL
Intervention: Aerobic exercise intervention
Number of subjects: 173

Group type: COMPARATOR
Intervention: Stretching control group
Number of subjects: 173
Study: 11597011

Group type: EXPERIMENTAL
Intervention: Radioactive Seed Localization (RSL)
Number of subjects: 97

Group type: COMPARATOR
Intervention: Wire Localization (WL)
Number of subjects: 97
Study: 9521394

Group type: EXPERIMENTAL
Intervention: Vaginal dinoprostone
Number of subjects: 0

Group type: COMPARATOR
Intervention: Oral misoprostol
Number of subjects: 0
Study: 7805083

Group type: EXPERIMENTAL
Intervention: Prophylaxis against venous thrombosis (mechanical and pharmacologic modalities)
Number of subjects: 200000

Group type: EXPERIMENTAL
Intervention: Therapy for DVT based on anatomic extent of thrombus
Number of subjects: 200000
Study: 2642875

Group type: EXPERIMENTAL
Intervention: sucralfate + ethanol
Number of subjects: 12

Group type: EXPERIMENTAL
Intervention: sucralfate + ethanol placebo
Number of subjects: 12

Group type: COMPARATOR
Intervention: sucralfate placebo + ethanol
Number of subjects: 12

Group type: COMPARATOR
Intervention: sucralfate placebo + ethanol placebo
Number of subjects: 12

Group type: EXPERIMENTAL
Intervention: sucralfate
Number of subjects: 12

Group type: COMPARATOR
Intervention: ethanol
Number of subjects: 12
Study: 1086428

Group type: EXPERIMENTAL
Intervention: Total shunt
Number of subjects: 48

Group type: EXPERIMENTAL
Intervention: Selective shunt (performed)
Number of subjects: 48

Group type: COMPARATOR
Intervention: Selective shunt (randomized)
Number of subjects: 48
Study: 31726034

Group type: EXPERIMENTAL
Intervention: EGP‐437 delivered by iontophoresis (days 0 and 7)
Number of subjects: 193

Group type: COMPARATOR
Intervention: Topical prednisolone acetate 1% (PA 1%) self-administered daily (tapered schedule, days 0‐28)
Number of subjects: 193

Group type: EXPERIMENTAL
Intervention: EGP‐437
Number of subjects: 193

Group type: COMPARATOR
Intervention: Topical prednisolone acetate 1% (PA 1%)
Number of subjects: 193
Study: 28481825

Group type: EXPERIMENTAL
Intervention: Nurse-led telephone follow-up education program (NP-FEP), contacted by telephone 11 times over a 6-month period.
Number of subjects: 403

Group type: COMPARATOR
Intervention: Conventional follow-up education (control group).
Number of subjects: 403
Study: 27855719

Group type: EXPERIMENTAL
Intervention: Illness-focused interactive booklet
Number of subjects: 20000

Group type: COMPARATOR
Intervention: Care as usual (control)
Number of subjects: 20000
Study: 24643710

Group type: EXPERIMENTAL
Intervention: Helmet therapy
Number of subjects: 186
Study: 22859320

Group type: EXPERIMENTAL
Intervention: Original salbutamol (5 mg, 20 drops in nebulizing solution)
Number of subjects: 126

Group type: COMPARATOR
Intervention: Similar salbutamol (5 mg, 20 drops in nebulizing solution)
Number of subjects: 126

Group type: EXPERIMENTAL
Intervention: Original salbutamol
Number of subjects: 126

Group type: COMPARATOR
Intervention: Similar salbutamol
Number of subjects: 126

Group type: EXPERIMENTAL
Intervention: Original salbutamol vs Similar salbutamol
Number of subjects: 126
Study: 21211337

Group type: EXPERIMENTAL
Intervention: Intratympanic methylprednisolone injection (62.5 mg/ml) infused at a rate of 10 microl/h for 14 days
Number of subjects: 113

Group type: COMPARATOR
Intervention: Control group (no specific intervention mentioned)
Number of subjects: 113
Study: 18498922

Group type: EXPERIMENTAL
Intervention: Abatacept
Number of subjects: 590

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 590
Study: 15711315

Group type: EXPERIMENTAL
Intervention: Finasteride (Proscar)
Number of subjects: 2981

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 2981
Study: 12742294

Group type: EXPERIMENTAL
Intervention: Beta-blockers
Number of subjects: 12

Group type: EXPERIMENTAL
Intervention: ACE inhibitors
Number of subjects: 12

Group type: COMPARATOR
Intervention: Bucindolol (a beta-blocker)
Number of subjects: 12